ORCID
- Hobart, Jeremy: 0000-0002-2114-7920
DOI
10.1007/s40263-018-0586-5
Publication Date
2019-01-01
Publication Title
CNS Drugs
Volume
33
Issue
1
First Page
61
Last Page
79
ISSN
1172-7047
Embargo Period
2019-02-12
Organisational Unit
Peninsula Medical School
Recommended Citation
Hobart, J., Ziemssen, T., Feys, P., Linnebank, M., Goodman, A., Farrell, R., Hupperts, R., Blight, A., Englishby, V., McNeill, M., Chang, I., & Elkins, J. (2019) 'Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-blind, Phase III ENHANCE Trial of Prolonged-release Fampridine', CNS Drugs, 33(1), pp. 61-79. Available at: https://doi.org/10.1007/s40263-018-0586-5
